Sign In
Buy ALNY
$291.22
-6.47 (-2.17%)
At Close: Jun 10, 2026
Alnylam Pharma Reports 2022 Product And Pipeline Goals
12:46pm, Friday, 19'th Nov 2021 FinanzNachrichten
WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) said it expects to achieve FDA approval for Vutrisiran in early 2022 for the treatment of the polyneuropathy of hATTR amyloidosis in adu
Alnylam Pharma Reports 2022 Product And Pipeline Goals - Quick Facts
12:25pm, Friday, 19'th Nov 2021 Business Insider Markets
(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) said it expects to achieve FDA approval for Vutrisiran in early 2022 for the treatment of the polyneuropathy of hATTR amyloidosis in adults. The PDUFA date is April 14, 2022. The company plans to launch vutrisiran in the U.S. in early 2022. Alnylam plans to file a supplementary New Drug
Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day
12:00pm, Friday, 19'th Nov 2021 Kwhen Finance
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Gap Up to $172.73
04:35pm, Thursday, 18'th Nov 2021 Dakota Financial News
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)s stock price gapped up prior to trading on Thursday . The stock had previously closed at $172.73, but opened at $180.00. Alnylam Pharmaceuticals shares last traded at $183.52, with a volume of 9,721 shares changing hands. ALNY has been the subject of a number of analyst reports. Piper Sandler downgraded shares []
Alnylam Pharma is said to be a potential target for Novartis - Bloomberg
12:19pm, Thursday, 18'th Nov 2021 Seeking Alpha
Industry Insights A report titled, Global Amyloidosis Therapeutics Market Outlook 2022 has been recently published by QY Research. The dedicated analysts and researchers have carried out deep-seated research to put forth the present and future scenario of the Amyloidosis Therapeutics
What's Happening With Alnylam Stock?
06:30am, Monday, 01'st Nov 2021
The stock price of Alnylam Pharmaceuticals, a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, plunged over 15% in yesterday's trading session, followi
Alnylam's (ALNY) Q3 Earnings & Revenues Fall Shy of Estimates
12:14pm, Friday, 29'th Oct 2021
Alnylam's (ALNY) earnings and sales miss estimates in the third quarter of 2021. The company reiterates its financial guidance for 2021.
Why Alnylam Pharmaceuticals Stock Is Tanking This Week
06:04am, Friday, 29'th Oct 2021
The company missed analysts' Q3 revenue expectations and announced the departure of its CEO.
Why Alnylam Pharmaceuticals Is Crashing Today
01:48pm, Thursday, 28'th Oct 2021
The company's earnings fell short of expectations and its CEO is leaving.
Alnylam to Webcast Conference Call Discussing Third Quarter 2021 Financial Results
08:00am, Thursday, 14'th Oct 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter endi
Alnylam: Potential Is In Line With Current Valuation
12:22pm, Thursday, 07'th Oct 2021
Alnylam is seeing sales ramp and could get more drugs approved in January and April 2022.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new pre-clinical research results demonstrating continued RNAi t
Alnylam to Webcast Presentation at Chardan Virtual 5th Annual Genetic Medicines Conference
04:00pm, Tuesday, 28'th Sep 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Chardan V
Alnylam (ALNY) Files MAA to EMA for Rare Disease Drug Vutrisiran
10:42am, Tuesday, 14'th Sep 2021
Alnylam (ALNY) submits a marketing authorization application to the EMA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
